Humana (NYSE:HUM) Downgraded by StockNews.com to Hold

Humana (NYSE:HUM) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Other equities analysts also recently issued reports about the stock. Truist Financial upped their target price on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Finally, Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $285.68.

Humana Price Performance

Shares of HUM stock opened at $264.39 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $31.91 billion, a P/E ratio of 26.57, a P/E/G ratio of 2.05 and a beta of 0.57. The company’s 50-day simple moving average is $271.39 and its two-hundred day simple moving average is $278.89. Humana has a one year low of $213.31 and a one year high of $406.46.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts anticipate that Humana will post 16.47 EPS for the current year.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. PKO Investment Management Joint Stock Co purchased a new position in shares of Humana during the fourth quarter worth $888,000. Siemens Fonds Invest GmbH raised its holdings in shares of Humana by 23.7% during the fourth quarter. Siemens Fonds Invest GmbH now owns 7,567 shares of the insurance provider’s stock worth $1,920,000 after purchasing an additional 1,448 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Humana during the fourth quarter worth $15,397,000. Forum Financial Management LP raised its holdings in shares of Humana by 62.0% during the fourth quarter. Forum Financial Management LP now owns 1,916 shares of the insurance provider’s stock worth $486,000 after purchasing an additional 733 shares during the last quarter. Finally, Toronto Dominion Bank raised its holdings in shares of Humana by 7.4% during the fourth quarter. Toronto Dominion Bank now owns 64,447 shares of the insurance provider’s stock worth $16,351,000 after purchasing an additional 4,455 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.